Cargando…

Praziquantel Treatment of Schistosoma mansoni Infected Mice Renders Them Less Susceptible to Reinfection

Beyond transient control of the infection, additional benefits of mass drug administration of praziquantel in endemic communities have been suggested in communities but not mechanistically investigated experimentally. The present study sought to evaluate the additional and hitherto unreported benefi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nono, Justin Komguep, Mpotje, Thabo, Mosala, Paballo, Aziz, Nada Abdel, Musaigwa, Fungai, Hlaka, Lerato, Spangenberg, Thomas, Brombacher, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703194/ https://www.ncbi.nlm.nih.gov/pubmed/34956183 http://dx.doi.org/10.3389/fimmu.2021.748387

Ejemplares similares

Schistosoma mansoni infection induces plasmablast and plasma cell death in the bone marrow and accelerates the decline of host vaccine responses
por: Musaigwa, Fungai, et al.
Publicado: (2022)

Investigating the antifibrotic effect of the antiparasitic drug Praziquantel in in vitro and in vivo preclinical models
por: Nono, Justin Komguep, et al.
Publicado: (2020)

Host regulation of liver fibroproliferative pathology during experimental schistosomiasis via interleukin-4 receptor alpha
por: Nono, Justin Komguep, et al.
Publicado: (2017)

Interleukin-4 receptor alpha is still required after Th2 polarization for the maintenance and the recall of protective immunity to Nematode infection
por: Nono, Justin Komguep, et al.
Publicado: (2017)

The Foxp3(+) regulatory T-cell population requires IL-4Rα signaling to control inflammation during helminth infections
por: Abdel Aziz, Nada, et al.
Publicado: (2018)

Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model
por: Abla, Nada, et al.
Publicado: (2017)

IL‐4Rα‐expressing CD11c(+) cells contribute to driving optimal cellular responses during Schistosoma mansoni infection in mice
por: Ndlovu, Hlumani, et al.
Publicado: (2018)

Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel
por: Amer, Eglal I., et al.
Publicado: (2022)

THE SUSCEPTIBILITY OF RECENT ISOLATES OF Schistosoma mansoni TO PRAZIQUANTEL
por: MENDONÇA, Adriana Maria B., et al.
Publicado: (2016)

The Role of Efflux Pumps in Schistosoma mansoni Praziquantel Resistant Phenotype
por: Pinto-Almeida, António, et al.
Publicado: (2015)

Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome
por: Schneeberger, Pierre H. H., et al.
Publicado: (2018)

A single locus determines praziquantel response in Schistosoma mansoni
por: Chevalier, Frédéric D., et al.
Publicado: (2023)

Prevalence and Reinfection Rates of Schistosoma mansoni and Praziquantel Efficacy against the Parasite among Primary School Children in Sanja Town, Northwest Ethiopia
por: Woldegerima, Eden, et al.
Publicado: (2019)

Environmental and microbial factors influence affective and cognitive behavior in C57BL/6 sub-strains
por: Abdel Aziz, Nada, et al.
Publicado: (2023)

Praziquantel Treatment Decreases Schistosoma mansoni Genetic Diversity in Experimental Infections
por: Coeli, Regina, et al.
Publicado: (2013)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
por: Minzi, Omary Mashiku, et al.
Publicado: (2021)

Reduced Susceptibility to Praziquantel among Naturally Occurring Kenyan Isolates of Schistosoma mansoni
por: Melman, Sandra D., et al.
Publicado: (2009)

Synergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult Worms
por: Almeida, Giulliana T., et al.
Publicado: (2015)

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting
por: Amara, Rokaya O, et al.
Publicado: (2018)

Morphological Characteristics of Schistosoma mansoni PZQ-Resistant and -Susceptible Strains Are Different in Presence of Praziquantel
por: Pinto-Almeida, António, et al.
Publicado: (2016)

Efficacy and Safety of Praziquantel for Treatment of Schistosoma mansoni Infection among School Children in Tanzania
por: Mnkugwe, Rajabu Hussein, et al.
Publicado: (2019)

Schistosoma mansoni alter transcription of immunomodulatory gene products following in vivo praziquantel exposure
por: McCusker, Paul, et al.
Publicado: (2021)

Protein undernutrition reduces the efficacy of praziquantel in a murine model of Schistosoma mansoni infection
por: Kadji Fassi, Joseph Bertin, et al.
Publicado: (2022)

Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases
por: Guler, Reto, et al.
Publicado: (2018)

IL-4i1 Regulation of Immune Protection During Mycobacterium tuberculosis Infection
por: Hlaka, Lerato, et al.
Publicado: (2021)

Effect of Maternal Schistosoma mansoni Infection and Praziquantel Treatment During Pregnancy on Schistosoma mansoni Infection and Immune Responsiveness among Offspring at Age Five Years
por: Tweyongyere, Robert, et al.
Publicado: (2013)

In Vitro Praziquantel Test Capable of Detecting Reduced In Vivo Efficacy in Schistosoma mansoni Human Infections
por: Lamberton, Poppy H. L., et al.
Publicado: (2010)

Efficacy and Safety of Praziquantel in Preschool-Aged Children in an Area Co-Endemic for Schistosoma mansoni and S. haematobium
por: Coulibaly, Jean T., et al.
Publicado: (2012)

Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug Administration
por: Crellen, Thomas, et al.
Publicado: (2016)

In vivo assessment of the antischistosomal activity of curcumin loaded nanoparticles versus praziquantel in the treatment of Schistosoma mansoni
por: Mokbel, Kamal El-Din M., et al.
Publicado: (2020)

The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic activity of praziquantel and artesunate against Schistosoma mansoni
por: Gouveia, Maria João, et al.
Publicado: (2019)

Efficacy of Single-Dose Praziquantel for the Treatment of Schistosoma mansoni Infections among School Children in Rwanda
por: Kabatende, Joseph, et al.
Publicado: (2023)

Schistosoma haematobium infection morbidity, praziquantel effectiveness and reinfection rate among children and young adults in Gabon
por: Dejon-Agobé, Jean Claude, et al.
Publicado: (2019)

Schistosoma mansoni reinfection: Analysis of risk factors by classification and regression tree (CART) modeling
por: Gazzinelli, Andréa, et al.
Publicado: (2017)

Comparison of the in vitro Effects of One-day Exposure to Amodiaquine and Praziquantel on Schistosoma mansoni Adult Worm Pairs
por: Mitsui, Yoshinori
Publicado: (2014)

Praziquantel sensitivity of Kenyan Schistosoma mansoni isolates and the generation of a laboratory strain with reduced susceptibility to the drug
por: Mwangi, Ibrahim N., et al.
Publicado: (2014)

Evaluation of the Anti-schistosomal Effects of Turmeric (Curcuma longa) Versus Praziquantel in Schistosoma mansoni Infected Mice
por: HUSSEIN, Atef, et al.
Publicado: (2017)

The effects of subcurative praziquantel treatment on life‐history traits and trade‐offs in drug‐resistant Schistosoma mansoni
por: Viana, Mafalda, et al.
Publicado: (2017)

Complementary Effect of Capparis Spinosa L. and Silymarin With/without Praziquantel on Mice Experimentally Infected with Schistosoma Mansoni
por: El-Hawary, S. S., et al.
Publicado: (2018)

Praziquantel is an effective drug for the treatment of Schistosoma Mansoni infection among school-aged children in Northwest Ethiopia
por: Tesfie, Addisu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ukkkihskhmtcfmuohoe88nnl1h